Clinical Trials Logo

Patient Starting Bevacizumab clinical trials

View clinical trials related to Patient Starting Bevacizumab.

Filter by:
  • None
  • Page 1

NCT ID: NCT03842917 Completed - Cancer Clinical Trials

SAlt Diet and Various Biomarkers Effects on Blood Pressure and Proteinuria During Inhibition of VEGF)

SAVE
Start date: April 26, 2019
Phase:
Study type: Observational

Bevacizumab is an anti-angiogenic treatment used to treat various solid cancers. Previous studies have shown that this treatment may have adverse effects like hypertension and proteinuria. This is an exploratory study aiming to better understand the relationship between various biomarkers and blood pressure changes and proteinuria measured for 4 to 6 weeks after the first infusion of anti-VEGF therapy with bevacizumab.